Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.

Claire H Pernar, Tamara L Lotan, Michelangelo Fiorentino, Konrad H Stopsack, Kathryn L Penney, Lorelei A Mucci, Colleen B McGrath, Hannah E Guard, Alaina H Shreves, Megan R Shanahan, Manelisi V Nhliziyo

Journal: International journal of cancer 2025;156(10):1898-1908

PMID: 39663641

Free Full Text on PubMed Central View on PubMed

Abstract

The most common somatic alteration in primary prostate cancer is the TMPRSS2:ERG gene fusion, which may be caused or promoted by distinct etiologic factors. The objective of this systematic review was to assess epidemiologic evidence on etiologic factors for prostate cancer by tumor TMPRSS2:ERG fusion status in human populations. Of 3071 publications identified, 19 cohort or case-control studies from six distinct study populations were included in this systematic review. Etiologic factors included germline genetic variants, circulating hormones, and dietary and lifestyle factors. Taller height, higher total and free testosterone levels, and fewer trinucleotide repeats in AR were possibly associated with higher risk of TMPRSS2:ERG-positive prostate cancer. Excess body weight, greater vigorous physical activity, higher lycopene intake, and the use of calcium channel blockers were associated with lower risk of TMPRSS2:ERG-positive prostate cancer. Diabetes and family history of prostate cancer were associated with both TMPRSS2:ERG-positive and TMPRSS2:ERG-negative prostate cancer. Prostate cancer germline variants had suggestive differential associations with TMPRSS2:ERG-positive or TMPRSS2:ERG-negative prostate cancer. However, results were based on few distinct study populations and generally had low precision, underscoring the need for replication. In conclusion, prostate cancer with TMPRSS2:ERG fusion is an etiologically distinct subtype that may be, in part, preventable by addressing modifiable and hormonally acting etiologic factors that align with the established mechanistic role of TMPRSS2:ERG in androgen, insulin, antioxidant, and growth factor pathways.

Address: Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.; Nuffield Department of Population Health, University of Oxford, Oxford, UK.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; Discovery Sciences, American Cancer Society, Atlanta, GA, USA.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.; Department of Epidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology-BIPS and Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany.

DOI: 10.1002/ijc.35279

Link outs

Free resources

Full Text Sources:

https://pmc.ncbi.nlm.nih.gov/articles/pmid/3966364...

Medical:

https://medlineplus.gov/prostatecancer.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-AKR1B1-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Male, Prostatic Neoplasms, Risk Factors, Oncogene Proteins, Fusion, Transcriptional Regulator ERG, Genetic Predisposition to Disease, Serine Endopeptidases